Skip to main content
SpringerLink
Log in

Effect of bedtime melatonin consumption on diabetes control and lipid profile

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Hormonal change in carbohydrate metabolism through the circadian rhythm is well known. An impaired nocturnal insulin secretion and lower level melatonin coexist in diabetics at the end of the night period. Administration of melatonin may improve impaired insulin secretion and control hyperglycemia. In a randomized, double-blind study, 64 type 2 tics were treated for 12 weeks (period 1) with placebo, and then for another 12 weeks (period 2) with 6 mg of melatonin. Fasting blood glucose (FBG), total triglyceride (TG), total cholesterol (CHOL), high-density (HDL), and low-density lipoprotein (LDL) cholesterol and glycosylated hemoglobin levels (HbA1c) were measured at baseline, 12 and 24 weeks. Following 3 months of melatonin treatment, mean HbA1c (±standard error) was significantly lower than at baseline (7.65 % ± 0.086 % versus 7.1 % ± 0.111 %, respectively, P = 0.0001). The mean FBG level was significantly decreased at the end of the study (164 ± 5.4 versus 157 ± 5.5, respectively, P < 0.001). The HDL cholesterol level increased at the end of the study (42 ± 1.3 versus 45 ± 1.39, respectively, P < 0.05) but no significant changes in TG, CHOL, and LDL were observed. Results showed that bed time melatonin administration in patients with type 2 diabetes, improved control of diabetes. Trial registration: IRCT2012062610115N1, http://en.search.irct.ir/search?query=melatonin+and+rezvanfar

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15(4):432–7.

    Article  CAS  PubMed  Google Scholar 

  2. Mulder H, Nagorny CL, Lyssenko V, et al. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia. 2009;52:1240–9.

    Article  CAS  PubMed  Google Scholar 

  3. Radziuk J, Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia. 2006;49:1619–28.

    Article  CAS  PubMed  Google Scholar 

  4. Lima FB, Machado UF, Bartol I, et al. Pinealectomy causes lucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Phys. 1998;275:934–41.

    Google Scholar 

  5. Rasmussen DD, Boldt BM, Wilkinson CW, et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology. 1999;140:1009–12.

    Article  CAS  Google Scholar 

  6. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin resistant mice. Endocrinology. 2009;150(12):5311–7.

    Article  CAS  PubMed  Google Scholar 

  7. Cagnacci A, Arangino S, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of post-menopausal women. Clin Endocrinol. 2001;54(3):339–46.

    Article  CAS  Google Scholar 

  8. Javier E, José A, Pariente A, et al. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes. 2011;2(6):82–91.

    Article  Google Scholar 

  9. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res. 2008;44(1):26–40.

    CAS  PubMed  Google Scholar 

  10. Robeva R, Kirilov G, Tomova A, et al. Melatonin-insulin interactions in patients with metabolic syndrome. J Pineal Res. 2008;44(1):52–6.

    CAS  PubMed  Google Scholar 

  11. Agil A, Rosado I, Ruiz R, et al. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. 2012;52(2):203–10.

    Article  CAS  PubMed  Google Scholar 

  12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):S81–90.

    Article  Google Scholar 

  13. Hussain SA, Khadim HM, Khalaf BH, et al. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J. 2006;27(10):1483–8.

    PubMed  Google Scholar 

  14. Nishida S, Segawa T, Murai I, et al. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of delta-5 desaturase activity. J Pineal Res. 2002;32(1):26–33.

    Article  CAS  PubMed  Google Scholar 

  15. Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, Intraabdominal adiposity, and plasma leptin and insulin independent of food intake and Total body Fat1. Endocrinology. 2000;141(2):487–97.

    CAS  Google Scholar 

  16. Nogueira TC, Lellis-Santos C, Jesus DS, et al. Absence of melatonin induces night-time hepatic insulin resistance and increased gluconeogenesis due to stimulation of nocturnal unfolded protein response. Endocrinology. 2011;152(4):1253–63.

    Article  CAS  PubMed  Google Scholar 

  17. Bazwinsky-Wutschke I, Bieseke L, et al. Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. J Pineal Res. 2014;56(1):82–96.

    Article  CAS  PubMed  Google Scholar 

  18. Sinha N, Mishra T, Singh T, et al. Effect of iron deficiency anemia on hemoglobin A1c level. Ann Lab Med 2012; 32: 17–22. [PMC free article]

  19. Tamura H, Nakamura Y, Narimatsu A, et al. Melatonin treatment in peri- and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. J Pineal Res. 2008;45(1):101–5.

    Article  CAS  PubMed  Google Scholar 

  20. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tang Y, Meng L, Li D, et al. Interaction of sleep quality and sleep duration on glycemic control in patients with type 2 diabetes mellitus. Chin Med J. 2014;127(20):3543–7.

    PubMed  Google Scholar 

  22. Tsai YW, Kann NH, Tung TH, et al. Impact of subjective sleep quality on glycemic control in type 2 diabetes mellitus. Fam Pract. 2012;29(1):30–5. doi:10.1093/fampra/cmr041.

    Article  PubMed  Google Scholar 

  23. Yoda K, Inaba M, Hamamoto K, et al. Association between poor glycemic control, impaired sleep quality, and increased arterial thickening in type 2 diabetic patients. PLoS ONE. 2015;10(4):e0122521. doi:10.1371/journal.pone.0122521.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27(1):87–98.

    Article  CAS  PubMed  Google Scholar 

  25. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci. 2007;64(10):1174–86.

    Article  CAS  PubMed  Google Scholar 

  26. Peschke E, Bähr I, Mühlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. J Pineal Res. 2015;59(1):1–23. doi:10.1111/jpi.12240.

    Article  CAS  PubMed  Google Scholar 

  27. Shweta Sharma, Hemant Sing, Nabeel Ahmad, et al. The role of melatonin in diabetes: therapeutic implications. Arch. Endocrinol. Metab. 59(5):391–9, 2015

  28. Lenters-Westra E, Slingerland RJ. Hemoglobin A1c point-of-care assays; a new world with a lot of consequences! J Diabetes Sci Technol. 2009;3(3):418–23.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology and Metabolism Research Center, Department of Internal medicine, School of Medicine, Arak University of Medical Sciences, Mellat 5, Hesabi Street, Arak, Iran

    Mohammad Reza Rezvanfar, Gila Heshmati, Ali Chehrei, Farshid Haghverdi, Fatemeh Rafiee & Faezeh Rezvanfar

Authors
  1. Mohammad Reza Rezvanfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gila Heshmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Chehrei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farshid Haghverdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatemeh Rafiee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Faezeh Rezvanfar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Reza Rezvanfar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezvanfar, M.R., Heshmati, G., Chehrei, A. et al. Effect of bedtime melatonin consumption on diabetes control and lipid profile. Int J Diabetes Dev Ctries 37, 74–77 (2017). https://doi.org/10.1007/s13410-016-0497-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-016-0497-2

Keywords

Search

Navigation